Synthetic lethality: targeting SMARCA2 ATPase in SMARCA4-deficient tumors – a review of patent literature from 2019–30 June 2023

References

• Clapier CR, Cairns BR. The biology of chromatin remodeling complexes. Annu revi biochem. 2009 Jun 01;78(1):273–304.
   PubMedGoogle Scholar
• He S, Wu Z, Tian Y, et al. Structure of nucleosome-bound human BAF complex. Science. 2020 Feb 21;367(6480):875–881. doi: 10.1126/science.aaz9761
   PubMed Web of Science ®Google Scholar
• Wang L, Yu J, Yu Z, et al. Structure of nucleosome-bound human PBAF complex. Nat Commun. 2022 Dec 10;13(1):7644. doi: 10.1038/s41467-022-34859-5
   PubMedGoogle Scholar
• Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nature Genet. 2013 Jun 01;45(6):592–601. doi: 10.1038/ng.2628
   PubMed Web of Science ®Google Scholar
• Kadoch C, Crabtree GR. Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci adv. 2015;1(5):e1500447. doi: 10.1126/sciadv.1500447
   PubMed Web of Science ®Google Scholar
• Shain AH, Pollack JR, Kashanchi F. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS One. 2013;8(1):e55119. doi: 10.1371/journal.pone.0055119
   PubMed Web of Science ®Google Scholar
• Hodges C, Kirkland JG, Crabtree GR. The many roles of BAF (mSWI/SNF) and PBAF complexes in cancer. Cold Spring Harb Perspect Med. 2016;6(8):a026930. doi: 10.1101/cshperspect.a026930
   PubMed Web of Science ®Google Scholar
• Schoenfeld AJ, Bandlamudi C, Lavery JA, et al. The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer. Clin Cancer Res. 2020;26(21):5701–5708. doi: 10.1158/1078-0432.CCR-20-1825
   PubMed Web of Science ®Google Scholar
• Hoffman GR, Rahal R, Buxton F, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc Nat Acad Sci. 2014 Feb 25;111(8):3128–3133. doi: 10.1073/pnas.1316793111
   PubMed Web of Science ®Google Scholar
• Vangamudi B, Paul TA, Shah PK, et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI/SNF-Mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 2015;75(18):3865–3878. doi: 10.1158/0008-5472.CAN-14-3798
   PubMed Web of Science ®Google Scholar
• Cantley J, Ye X, Rousseau E, et al. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nat Commun. 2022 Nov 10;13(1):6814. doi: 10.1038/s41467-022-34562-5
   PubMed Web of Science ®Google Scholar
• Kofink C, Trainor N, Mair B, et al. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nat Commun. 2022 Oct 10;13(1):5969. doi: 10.1038/s41467-022-33430-6
   PubMed Web of Science ®Google Scholar
• Braeuer N, Ehrmann AHM, Gorjanacz M, et al., inventors; Bayer Aktiengesellschaft, assignee. Urea derivatives for cancer therapy patent. WO2020126968. 2020.
   Google Scholar
• Moradei O, Lampe JW, Harvey DM, et al., inventors; Epizyme, Inc., assignee. Pyridin-2-one compounds useful as SMARCA2 antagonists and their preparation patent. WO2020023657. 2020.
   Google Scholar
• Anthony NJ, Millan DS, Vaswani RG, et al., inventors; Foghorn Therapeutics Inc., assignee. Preparation of thiazolyl aminocarbamates for the treatment of BAF complex-related disorders patent. WO2019152437. 2019.
   Google Scholar
• Vaswani RG, Anthony NJ, Millan DS, et al., inventors; Foghorn Therapeutics Inc., assignee. Preparation of acylamino acid heterocyclyl amides for the treatment of BAF complex-related disorders patent. WO2020160180. 2020.
   Google Scholar
• Anthony NJ, Vaswani RG, Millan DS, et al., inventors; Foghorn Therapeutics Inc., assignee. Preparation of thiazole aminopyrroles and thiazole aminoindoles useful in treatment of BAF complex-related disorders patent. WO2020160100. 2020.
   Google Scholar
• Centore RC, Xu L, Lahr D, inventors; Foghorn Therapeutics Inc., assignee. Methods of treating cancers using an agent that reduces the level and/or activity of BRG1 and/or BRM patent. WO2020106915. 2020.
   Google Scholar
• Anthony NJ, Vaswani RG, Millan DS, et al., inventors; Foghorn Therapeutics Inc., assignee. Benzamide compounds for the treatment of BAF complex-related diseases and their preparation patent. WO2021155316. 2021.
   Google Scholar
• Vaswani RG, Huang DS, inventors; Foghorn Therapeutics Inc., assignee. Preparation of acylamino acid heterocyclyl amides and deuterated derivatives for the treatment of BAF complex-related disorders patent. US20210230154. 2021.
   Google Scholar
• Centore RC, Xu L, Lahr D, et al., inventors; Foghorn Therapeutics Inc., assignee. Methods of treating cancers patent. WO2021236080. 2021.
   Google Scholar
• Vaswani RG, Gu C-H, inventors; Foghorn Therapeutics Inc., assignee. Crystalline forms, compositions containing same, and methods of their use patent. WO2022192365. 2022.
   Google Scholar
• Huang L, inventor; Foghorn Therapeutics Inc., assignee. Therapeutic regimens of an acylserine heterocyclyl amide inhibitor of the enzymatic activity of BRG1 and BRM patent. WO2022198043. 2022.
   Google Scholar
• Adam A, Ichikawa K, Hentemann MF, et al., inventors; Foghorn Therapeutics Inc., assignee. Methods of treating cancer including administering an agent that decreases BRM/BRG1 in combination with immunotherapy patent. WO2023009834. 2023.
   Google Scholar
• Vaswani RG, Huang DS, Wilson KJ, et al., inventors; Foghorn Therapeutics Inc., assignee. Compounds and uses thereof for treatment of complex-related disorders patent. WO2021155264. 2021.
   Google Scholar
• Wilson KJ, Schiller SER, Negretti S, inventors; Foghorn Therapeutics Inc., assignee. Carboxamide compounds for the treatment of BAF complex-related diseases and their preparation patent. WO2021155320. 2021.
   Google Scholar
• Wilson KJ, Negretti S, Schiller SER, et al., inventors; Foghorn Therapeutics Inc., assignee. Preparation of substituted benzoxathiepinecarboxamides useful for modulating BRG1- or BRM-associated factors (BAF) complexes patent. WO2022103899. 2022.
   Google Scholar
• Adair C, Papillon J, Nakajima K, et al., inventors; Novartis AG, assignee. Preparation of substituted 1-(isothiazol-5-yl)-3-(pyridin-4-yl)ureas and compositions as SMARCA2/BRMAtpase inhibitors patent. WO2020035779. 2020.
   Google Scholar
• Papillon JPN, Nakajima K, Adair CD, et al. Discovery of orally active inhibitors of brahma homolog (BRM)/SMARCA2 ATPase activity for the treatment of brahma related gene 1 (BRG1)/SMARCA4-mutant cancers. J Med Chem. 2018 Nov 21;61(22):10155–10172. doi: 10.1021/acs.jmedchem.8b01318
   PubMed Web of Science ®Google Scholar
• Li D, Dai L, Qi J, inventors; Dana-Farber Cancer Institute, Inc., assignee. Preparation of bifunctional PROTAC compounds, compositions, and methods for degradation of targeted SMARCA2, SMARCA4 or BRM proteins patent. WO2021163302. 2021.
   Google Scholar
• Netherton M, SEr S, Deng J, et al., inventors; Foghorn Therapeutics Inc., assignee. Heteroaromatic compounds for the treatment of BAF complex-related diseases and their preparation patent. WO2021155321. 2021.
   Google Scholar
• Ji N, Zhang Y, Weiss MM, et al., inventors; Kymera Therapeutics, Inc., assignee. Preparation of heterocyclic compounds as SMARCA degraders and uses thereof patent. WO2020251971. 2020.
   Google Scholar
• Zhang Y, Zheng X, Zhu X, inventors; Kymera Therapeutics, Inc., assignee. SMARCA degraders and their uses patent. WO2022125800. 2022.
   Google Scholar
• Zhang Y, inventor; Kymera Therapeutics, Inc., assignee Amide compounds as Smarca degraders and their preparation, pharmaceutical compositions and use in the treatment of diseases patent. WO2022178532. 2022.
   Google Scholar
• Foghorn Therapeutics. FHD-286 as monotherapy or combination therapy in subjects with advanced hematologic malignancies Bethesda (MD): U.S. National Library of Medicine; 2021. Available from: https://clinicaltrials.gov/study/NCT04891757
   Google Scholar
• Foghorn Therapeutics. FHD-286 in subjects with metastatic uveal melanoma. Bethesda (MD): U.S. National Library of Medicine; 2021. Available from: https://clinicaltrials.gov/study/NCT04879017
   Google Scholar
• Foghorn therapeutics announces clinical data from phase 1 study of FHD-286 in metastatic uveal melanoma [Internet]. 2023 Jun 28. Available from: https://ir.foghorntx.com/news-releases/news-release-details/foghorn-therapeutics-announces-clinical-data-phase-1-study-fhd
   Google Scholar
• Kana I, Ammar A, Hsin-Jung W, et al. 888 Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models. J Immunother Cancer. 2022;10(Suppl 2):A925.
   Google Scholar
• Zhou M, Yuan J, Deng Y, et al. Emerging role of SWI/SNF complex deficiency as a target of immune checkpoint blockade in human cancers. Oncogenesis. 2021 Jan 08;10(1):3. doi: 10.1038/s41389-020-00296-6
   PubMed Web of Science ®Google Scholar
• Foghorn provides pipeline update on FHD-909 BRM selective inhibitor [Internet]. 2024 Feb 8. Available from: https://ir.foghorntx.com/news-releases/news-release-details/foghorn-provides-pipeline-update-fhd-909-brm-selective-inhibitor
   Google Scholar